Bio­gen ex­pects to re­duce head­count by 1,000 un­der $700M op­er­a­tional sav­ings plan 

Fresh off two FDA green lights — a full ap­proval for Alzheimer’s and an ac­cel­er­at­ed nod in ALS — Bio­gen CEO Chris Viehbach­er is bring­ing down the bud­get axe and will shrink head­count by about 1,000 by 2025.

Bio­gen is im­ple­ment­ing a ma­jor ex­pand­ed re­duc­tion plan, hop­ing to save $700 mil­lion in net op­er­at­ing ex­pens­es by 2025. An­oth­er $300 mil­lion is ex­pect­ed to be saved, but will be re-in­ject­ed in­to prod­uct launch­es and R&D, the com­pa­ny said Tues­day morn­ing dur­ing sec­ond quar­ter earn­ings. The famed Boston drug­mak­er gen­er­at­ed $2.45 bil­lion in rev­enue in the sec­ond quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER